Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines

Leukemia and Lymphoma

Volumn 51, Issue 4, 2010, Pages 671-679

  Civallero, Monica ^a   Cosenza, Maria ^a   Grisendi, Giulia ^a   Marcheselli, Luigi ^a   Todoerti, Katia ^b   Sacchi, Stefano ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Apoptosis; B cell lines; Indolent lymphoma; PI3K AKT; PKC; Signaling pathways

Indexed keywords

CHLORAMBUCIL; ENZASTAURIN; FLUDARABINE; PROTEIN BAD; PROTEIN KINASE B; PROTEIN KINASE C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; LYMPHOMA, B-CELL; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 77953212331     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003637290     Document Type: Article

References (30)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p i85
2. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24: 1582-1589.
3. Sacchi S, Pozzi S, Marcheselli L, et al.; Italian Lymphoma Study Group. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077-2082.
4. Barosi G, Carella A, Lazzarino M, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005;90: 1236-1257.
5. Baldini L, Brugiatelli M, Luminari S, et al.; Gruppo Italiano per lo Studio dei Linfomi. Treatment of indolent B-cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol 2003;21:1459-1465.
6. Goldaniga M, Merli F, Stelitano C, et al. Front-line treatment of low-grade non-follicular non-Hodgkin lymphoma (final report of Gisl LL02 trial). Blood 2007;110(Suppl. 1):690a (Abstract 2332).
7. Baldini L, Pulsoni A, Rossi G, et al. Front-line chemoimmunotherapy rituximab-FCprituximab maintenance in patients with untreated advanced stage non follicular lymphoma (INFL): preliminary results of a prospective study of the Intergruppo Italiano Linfomi and Roche (ML18324). Blood 2008;112(Suppl. 1):709 (Abstract 2686).
8. Meijerink JP. t(14;18), a journey to eternity. Leukemia 1997; 11:2175-2187.
9. da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002;7: 17-33.
10. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
11. Li S, Phong M, Lahn M, et al. Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B cell lymphomas. Biol Direct 2007;21:2-8.
12. Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science 1996; 273:788-791.
13. Faul MM, Gillig JR, Jirousek MR, et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCb. Bioorg Med Chem Lett 2003;13:1857-1859.
14. Yoshiji H, Kuriyama S, Ways DH, et al. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999;59:4413-4418.
15. Gartner S, Kaplan HS. Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 1980;77:4756-4759.
16. Cremer T, Lichter P, Borden J, Ward DC, Manuelidis L. Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes. Hum Genet 1988;80:235-246.
17. Gribben JG, Freedman A, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991;78:3275-3280.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
20. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:7462-7469.
21. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl). Blood 2007;109:1669-1677.
22. Morgillo F, Martinelli E, Troiani T, et al. Sequencedependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C beta inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther 2008;7:1698-1707.
23. Querfeld C, Rizvi MA, Kuzel TM, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006;126:1641-1647.
24. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-1789.
25. Neri A, Marmiroli S, Tassone P, et al. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma 2008;49:1374-1383.
26. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell 1996;87:619-628.
27. Tan Y, Ruan H, Demeter MR, Comb MJ. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem 1999;274:34859- 34867.
28. Hurbin A, Coll JL, Dubrez-Daloz L, et al. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Baxand Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells. J Biol Chem 2005;280:19757-19767.
29. Lee KW, Kim SG, KimHP, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008;68:1916-1926.
30. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase Cb inhibitor, in patients with advanced cancer. J Clin Oncol 2006;24:4092-4099.